The withdrawal of the selective cyclooxygenase 2 inhibitor rofecoxib owing to cardiovascular side effects ignited debate about the need for major changes to current mechanisms for post-marketing surveillance (PMS) of drug safety. Here, we discuss the current mechanisms, whether they are being used appropriately, and consider the need for changes to regulatory systems.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709–1711 (2004).
Topol, E. J. Failing public health — rofecoxib, Merck and the FDA. N. Engl. J. Med. 351, 1707–1709 (2004).
Frantz, S. How to avoid another 'Vioxx'. Nature Rev. Drug Discov. 4, 5–7 (2005).
Belton, K. J. and the European Pharmacovigilance Research Group Attitude survey of adverse drug reaction reporting by health care professionals across the European Union. Eur. J. Clin. Pharmacol. 6, 423–427 (1997).
Mann, R. D. Prescription Event Monitoring — recent progress and future horizons. Br. J. Clin. Pharmacol. 46, 195–201 (1998).
Safety Assessment of Marketed Medicines. Guidelines for company sponsored safety assessment of marketed medicines. (London MCA, 1993).
Griffin, M. R., Stein, M. S. & Ray, W. A. Post marketing surveillance for drug safety; surely we can do better. Clin. Pharmacol. Ther. 75, 491–494 (2004)
Report of the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 45, 2004).
Jick, H., Kaye, J. & Jick, S. Antidepressants and the risk of suicidal behaviours. JAMA 292, 338–343 (2004)
Glaxo SmithKline. Report quoted in the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 103–104, 2004).
Martinez, C. et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case control study. Br. Med. J. 330, 389 (2005).
Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092–1102 (2005).
Rubenstein, S. How best to monitor drugs after they're FDA approved. Q&A Wall Street Journal (20 Dec 2004).
The authors declare no competing financial interests.
About this article
Cite this article
Breckenridge, A., Woods, K. & Raine, J. Monitoring the safety of licensed medicines. Nat Rev Drug Discov 4, 541–543 (2005). https://doi.org/10.1038/nrd1778
Nature Communications (2020)
Integrating Multiple Evidence Sources to Predict Adverse Drug Reactions Based on a Systems Pharmacology Model
CPT: Pharmacometrics & Systems Pharmacology (2015)
Japanese Journal of Thrombosis and Hemostasis (2013)
PLoS Medicine (2013)
Journal of the Neurological Sciences (2013)